Skip to main content
OpenTrials

Clinical trial condition

HER-2 Positive Breast Cancer

Explore clinical trials studying HER-2 Positive Breast Cancer. Study availability and eligibility vary by location and protocol.

19 public trials 1 recruiting study
Refine in advanced search Browse all conditions

HER-2 Positive Breast Cancer trial results

Completed

Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer

NCT01340430

Conditions
Disease Attributes, Disease Progression, HER-2 Positive Breast Cancer, +3 more
Locations
  • Istituto Nazionale per La Ricerca sul Cancro (IST) Genoa, Ge, Italy
  • Ospedale S. Maria della Misericordia - Oncologia Medica Perugia, PG, Italy
  • Fondazione del Piemonte per l'Oncologia - IRCC di Candiolo Candiolo, TO, Italy
  • Ospedale Ostetrico Ginecologico S. Anna Di Torino - Oncologia Medica Torino, To, Italy
View Trial Details
Completed

A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer

NCT00788931

Conditions
Breast Diseases, Breast Neoplasms, HER-2 Positive Breast Cancer, +5 more
Locations
  • Novartis Investigative Site Mobile, Alabama, United States
  • Novartis Investigative Site Woodville, South Australia, Australia
  • Novartis Investigative Site Brussels, Belgium
  • Novartis Investigative Site Liège, Belgium
View Trial Details
Completed

A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases

NCT01305941

Conditions
Brain Diseases, Brain Neoplasms, Breast Diseases, +10 more
Locations
  • University Of Alabama at Birmingham Birmingham, Alabama, United States
  • UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States
  • Carolinas Healthcare System Charlotte, North Carolina, United States
  • Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States
View Trial Details
Completed

An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer

NCT01677455

Conditions
Breast Cancer, Breast Diseases, Breast Neoplasms, +8 more
Locations
  • Synta Pharmaceuticals Investigative Site Birmingham, Alabama, United States
  • Synta Pharmaceuticals Investigative Site Altanta, Georgia, United States
  • Synta Pharmaceuticals Investigative Site Boston, Massachusetts, United States
  • Synta Pharmaceuticals Investigative Site New York, United States
View all 25 locations
View Trial Details
Completed

Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 Years

NCT01433926

Conditions
Breast Diseases, Breast Neoplasms, Disease Attributes, +9 more
Locations
  • Hospital oncológico de Galicia A Coruña, Spain
  • Hospital de Alcoy Virgen de los Lirios Alcoy, Alicante, Spain
  • Hospital Son Llatzer Palma de Mallorca, Balearic Islands, Spain
  • Hospital Germans Trias i Pujol Badalona, Barcelona, Spain
View all 39 locations
View Trial Details

Related conditions